Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Q2 2014 Earnings Presentation

24 slides from Sucampo Pharmaceuticals's earnings presentation, Aug 5, 2014

  1. Slide 1: Second Quarter 2014 Corporate Update and Financial Results

    Second Quarter 2014 Corporate Update and Financial Results August 5, 2014 e 3 SUCAMPO The Science of innovation

  2. Slide 2: Introductions and Forward-Looking Statements

    uctions and Forward- j Statements Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications e 3 SUCAMPO The Science of innovation

  3. Slide 3: Agenda

    Agenda Introductions and Forward-Looking ae Statements Silvia Taylor Corporate Update Peter Greenleaf Financial Performance Cary J. Claiborne Closing Remarks Peter Greenleaf $ sucampo The Science of innovation

  4. Slide 4: Forward-Looking Statements

    -Looking Statements This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ material

  5. Slide 5: Peter Greenleaf, Chief Executive Officer

    20: Peter Greenleaf Chief Executive Officer e 3 SUCAMPO The Science of innovation

  6. Slide 6: Over the Past Three Months the Organization Has Worked Methodically

    - Over the Past Three Months the Organization Has Viethodically to Develop a New Direttion.for. Where Do Our What Are Our Competitive What Is The 5 And Vision, Mission Advantages & 10 Year Strategy? & Values? Challenges Lie? See ie rategic Imperatives = “Investments _ WhatAre Our WhatAre Our Whetens

  7. Slide 7: Our Evolution

    Our Evolution Today * Global company with a propriety prostone technology * Commercial work in AMITIZA and RESCULA + Pipeline based on prostone technology + Acore capability of clinical development and regulatory success Future Vision A global, integrated biopharmaceutical company Leadership in Gl,

  8. Slide 8: Four Strategic Imperatives To Realize Our Vision

    Four Strategic Imperatives To Realize Our Vision 1. Focus our efforts and strengthen our overall capabilities 2. Secure and grow revenue from our flagship product, AMITIZA 3. Optimize our investment in prostone technology 4. Expand our pipeline and diversify our science $ sucampo 8 The Science of in

  9. Slide 9: Focus Our Efforts and Strengthen Our Capabilities

    Focus Our Efforts and Strengthen Our Capabilities Use our strong foundation to build from + Financial performance * Technology * People Strengthen the team and our development capability Focus our resources on areas that produce the best return on investment -— both short and long term + Exit certai

  10. Slide 10: Secure and Grow Revenue From AMITIZA

    Secure and Grow Revenue From AMITIZA Revenue from AMITIZA provides a stable and growing revenue base + Resolution on our patent litigation on AMITIZA is critical + Ensuring consistent and sustainable growth + Expand our commercial partnerships globally Exit direct selling and marketing of RESCULA *

  11. Slide 11: Optimize Our Investment in Prostone Technology

    Optimize Our Investment.in Prostone Technology. Accelerate and Prioritize: Accelerate AMITIZA life cycle management + Alternate formulation development * Pediatric program Create the best path for our ion channel activator programs Review interim data for unoprostone isopropyl for RP 1H 2015 * May o

  12. Slide 12: Diversify Our Science

    Diversify Our Science Commenced external assessment of new therapeutic areas and targets + Build from our core in GI and ophthalmology + Aggressively explore new pathways and TA’s + Consider both early (post POC) and mid-to-late stage assets $ sucampo 2 The Science of innovation

  13. Slide 13: Four Strategic Imperatives To Realize Our Vision

    Four Strategic Imperatives To Realize Our Vision 1. Focus our efforts and strengthen our overall capabilities 2. Secure and grow revenue from our flagship product, AMITIZA 3. Optimize our investment in prostone technology 4. Expand our pipeline and diversify our science $ sucampo The Science of inno

  14. Slide 14: Upcoming Milestones

    Upcoming Milestones 2014 Second Half + Progress global partnership agreements + Update on AMITIZA new formulation and pediatric functional constipation development + File AMITIZA (CIC and OIC) for approval in Canada + Initiate Mutual Recognition Procedure to secure approval for AMITIZA (CIC) in 29 a

  15. Slide 15: Value Creation

    impo’s Value Globally aligned organization + Clear and streamlined R&D strategy (prostone) + Re-alignment of + Execute on significant commercial emphasis & organic R&D globalalliancesin place + Growing suite of non- New program launches Prostone and non-prostone Pan ctenese davelcoreit prostone tech

  16. Slide 16: A Performance Update

    A 4 Performance Update Cary J. Claiborne Chief Financial Officer e 3 SUCAMPO The Science of innovation

  17. Slide 17: Net Income and EPS

    $0.05 $2.4 Q2-14 YTD-14 Q2-14 YTD-14 Net Income EPS $sucampo The Science of Innovation

  18. Slide 18: U.S. Net Sales ($M)

    AU.S. Net Sales* ($M) Q2-13 Q2-14 YTD-2013 YTD-2014 $ sucampo "8 *As reported by Takeda for royalty calculation purposes The Science of Innovation

  19. Slide 19: Revenue Highlights ($M)

    nue Highlights ($M) $13.9 $12.0 Q2-13 Q2-14 Q2-13 Q2-14 Product Royalty Product Sales Revenues Revenues $sucampo $7.2M= Japan | “se sales | Ase The Science of Innovation

  20. Slide 20: Revenue Highlights ($M) (cont.)

    enue Highlights ($M) (cont.) $27.0 | (85%) $11.5 = $1.7 Q2-13 Q2-14 Q2-13 Q2-14 R&D Revenues Total Revenues* $sucampo * *Co-promotion, contract and collaboration revenue also are components of revenue. The Science of Innovation

  21. Slide 21: Expenses and Income Summary

    (10.9%) COGS: increased volume of AMITIZA sales in » ‘ y Japan 99.0% j R&D expense: Lower costs in our lumbar spinal Revenue $27.0 Expenses | Costs of goods sold $19 R&D expense $44 G&A expense $6.0 Selling & Marketing expense 1 stenosis trials, partially offset by increased spending (9%) = associat

  22. Slide 22: Financial Guidance

    lancial Guidance Full Year 2014 GAAP Net Income $4M - S6M GAAP EPS $0.08- $0.13 $ sucampo 22 The Science of Innovation

  23. Slide 23: Peter Greenleaf, Chief Executive Officer

    Peter Greenleaf Chief Executive Officer e 3 SUCAMPO The Science of innovation

  24. Slide 24: ‘S SUCAMPO

    e ‘S SUCAMPO The Science of innovation

Sucampo Pharmaceuticals — Q2 2014 Earnings Presentation on 6ix